Johan F Vansteenkiste1, Jean-Luc Canon2, Filippo De Braud3, Francesco Grossi4, Tommaso De Pas5, Jhanelle E Gray6, Wu-Chou Su7, Enriqueta Felip8, Hiroshige Yoshioka9, Cesare Gridelli10, Grace K Dy11, Sumitra Thongprasert12, Martin Reck13, Paola Aimone14, Gena Atalla Vidam15, Pantelia Roussou14, Ying A Wang16, Emmanuelle Di Tomaso16, Jean-Charles Soria17. 1. University Hospitals KU Leuven, Leuven, Belgium. Electronic address: johan.vansteenkiste@uzleuven.be. 2. Grand Hôpital de Charleroi, Charleroi, Belgium. 3. Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. 4. AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. 5. European Institute of Oncology, Milan, Italy. 6. Moffitt Cancer Center, Tampa, Florida. 7. National Cheng Kung University Hospital, Tainan, Taiwan. 8. Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 9. Kurashiki Central Hospital, Kurashiki, Japan. 10. S.G. Moscati Hospital, Avellino, Italy. 11. Roswell Park Cancer Institute, Buffalo, New York. 12. Chiang Mai University, Chiang Mai, Thailand. 13. LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany. 14. Novartis Pharma AG, Basel, Switzerland. 15. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 16. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. 17. Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.
Abstract
INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients with PI3K pathway-activated, relapsed NSCLC. METHODS: After prescreening for PI3K pathway activation, patients with PI3K pathway-activated, metastatic, squamous or nonsquamous NSCLC, who had relapsed after prior systemic antineoplastic therapy, were enrolled. In Stage 1, patients received single-agent buparlisib (100 mg/day). A futility analysis was performed independently in each histology group, based on the 12-week progression-free survival rate for the first 30 patients treated in each group being less than 50%. Exploratory biomarker analyses were performed in archival tissue samples and circulating tumor DNA (ctDNA). RESULTS: Of 1242 prescreened patients, 13.5% exhibited PI3K pathway activation. As of June 5, 2014, 63 patients (30 squamous and 33 nonsquamous) were treated in Stage 1. The 12-week progression-free survival rates were 23.3% (95% confidence interval: 9.9-42.3) and 20.0% (95% confidence interval: 7.7-38.6) in the squamous and nonsquamous groups, respectively. Stage 2 was therefore not initiated in either group. PI3K pathway mutations in ctDNA were more concordant with metastatic tissue than with primary biopsies. CONCLUSIONS: Despite preselecting patients for targeted treatment, BASALT-1 did not meet its primary objective during Stage 1. PI3K pathway activation can be detected using ctDNA, but may not be the main oncogenic driver in NSCLC. Combinations of PI3K inhibitors with other agents may demonstrate greater efficacy than monotherapy.
INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients with PI3K pathway-activated, relapsed NSCLC. METHODS: After prescreening for PI3K pathway activation, patients with PI3K pathway-activated, metastatic, squamous or nonsquamous NSCLC, who had relapsed after prior systemic antineoplastic therapy, were enrolled. In Stage 1, patients received single-agent buparlisib (100 mg/day). A futility analysis was performed independently in each histology group, based on the 12-week progression-free survival rate for the first 30 patients treated in each group being less than 50%. Exploratory biomarker analyses were performed in archival tissue samples and circulating tumor DNA (ctDNA). RESULTS: Of 1242 prescreened patients, 13.5% exhibited PI3K pathway activation. As of June 5, 2014, 63 patients (30 squamous and 33 nonsquamous) were treated in Stage 1. The 12-week progression-free survival rates were 23.3% (95% confidence interval: 9.9-42.3) and 20.0% (95% confidence interval: 7.7-38.6) in the squamous and nonsquamous groups, respectively. Stage 2 was therefore not initiated in either group. PI3K pathway mutations in ctDNA were more concordant with metastatic tissue than with primary biopsies. CONCLUSIONS: Despite preselecting patients for targeted treatment, BASALT-1 did not meet its primary objective during Stage 1. PI3K pathway activation can be detected using ctDNA, but may not be the main oncogenic driver in NSCLC. Combinations of PI3K inhibitors with other agents may demonstrate greater efficacy than monotherapy.
Authors: Jordi Rodon; Irene Braña; Lillian L Siu; Maja J De Jonge; Natasha Homji; David Mills; Emmanuelle Di Tomaso; Celine Sarr; Lucia Trandafir; Cristian Massacesi; Ferry Eskens; Johanna C Bendell Journal: Invest New Drugs Date: 2014-03-21 Impact factor: 3.850
Authors: Carmen J Marsit; Shichun Zheng; Kenneth Aldape; Philip W Hinds; Heather H Nelson; John K Wiencke; Karl T Kelsey Journal: Hum Pathol Date: 2005-07 Impact factor: 3.466
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga Journal: Oncogene Date: 2003-05-08 Impact factor: 9.867
Authors: Martin L Sos; Stefanie Fischer; Roland Ullrich; Martin Peifer; Johannes M Heuckmann; Mirjam Koker; Stefanie Heynck; Isabel Stückrath; Jonathan Weiss; Florian Fischer; Kathrin Michel; Aviva Goel; Lucia Regales; Katerina A Politi; Samanthi Perera; Matthäus Getlik; Lukas C Heukamp; Sascha Ansén; Thomas Zander; Rameen Beroukhim; Hamid Kashkar; Kevan M Shokat; William R Sellers; Daniel Rauh; Christine Orr; Klaus P Hoeflich; Lori Friedman; Kwok-Kin Wong; William Pao; Roman K Thomas Journal: Proc Natl Acad Sci U S A Date: 2009-10-05 Impact factor: 11.205
Authors: Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Christopher R Zito; Lucia B Jilaveanu; Valsamo Anagnostou; David Rimm; Gerold Bepler; Sauveur-Michel Maira; Wolfgang Hackl; Robert Camp; Harriet M Kluger; Herta H Chao Journal: PLoS One Date: 2012-02-15 Impact factor: 3.240
Authors: M R Yun; H M Choi; H N Kang; Yw Lee; H-S Joo; D H Kim; H R Kim; M H Hong; S O Yoon; B C Cho Journal: Oncogene Date: 2017-09-25 Impact factor: 9.867
Authors: Lillian M Smyth; Kelsey R Monson; Komal Jhaveri; Alexander Drilon; Bob T Li; Wassim Abida; Gopa Iyer; John F Gerecitano; Mrinal Gounder; James J Harding; Martin H Voss; Vicky Makker; Alan L Ho; Pedram Razavi; Alexia Iasonos; Philip Bialer; Mario E Lacouture; Jerrold B Teitcher; Joseph P Erinjeri; Nora Katabi; Matthew G Fury; David M Hyman Journal: Invest New Drugs Date: 2017-03-09 Impact factor: 3.850
Authors: Emmet J Jordan; Hyunjae R Kim; Maria E Arcila; David Barron; Debyani Chakravarty; JianJiong Gao; Matthew T Chang; Andy Ni; Ritika Kundra; Philip Jonsson; Gowtham Jayakumaran; Sizhi Paul Gao; Hannah C Johnsen; Aphrothiti J Hanrahan; Ahmet Zehir; Natasha Rekhtman; Michelle S Ginsberg; Bob T Li; Helena A Yu; Paul K Paik; Alexander Drilon; Matthew D Hellmann; Dalicia N Reales; Ryma Benayed; Valerie W Rusch; Mark G Kris; Jamie E Chaft; José Baselga; Barry S Taylor; Nikolaus Schultz; Charles M Rudin; David M Hyman; Michael F Berger; David B Solit; Marc Ladanyi; Gregory J Riely Journal: Cancer Discov Date: 2017-03-23 Impact factor: 39.397